No Data
No Data
Canaccord Genuity Maintains Buy on Regulus Therapeutics, Maintains $28 Price Target
Is Regulus Therapeutics (NASDAQ:RGLS) In A Good Position To Invest In Growth?
Regulus Therapeutics | 10-K: FY2024 Annual Report
Regulus Therapeutics | 8-K: Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates
Express News | Regulus Therapeutics: Co Expects Its Cash Runway to Extend Into Early 2026
Express News | Regulus Therapeutics Q4 Basic EPS USD -0.2